Please use this identifier to cite or link to this item: 192.168.6.56/handle/123456789/417
Full metadata record
DC FieldValueLanguage
dc.contributor.editorEricka Johnson-
dc.date.accessioned2018-09-04T06:36:27Z-
dc.date.available2018-09-04T06:36:27Z-
dc.date.issued2017-
dc.identifier.isbn978-3-319-51487-1-
dc.identifier.urihttp://10.6.20.12:80/handle/123456789/417-
dc.descriptionThe title of this volume, Gendering Drugs, is a double entendre. It speaks to the idea that pharmaceuticals can be gendered—perceived as being masculine or feminine, for men or women—by the bodies and symptoms they are supposed to treat, by market forces and marketing campaigns, and by user demographics. Just think of the infamous little blue pill, Viagra, and the attempts to sell a pink version of the same blockbuster drug (Cacchioni 2015). The other meaning in the title suggests the ways that pharmaceuticals create gendered subjectivities for us, the users. Pharmaceuticals can articulate gendered values, norms, behaviors and expectations that we as users (or misusers, or resisters) must respond to in some way. Drugs can be gendered and they can engender us-
dc.languageenen_US
dc.language.isoenen_US
dc.publisherPalgrave Macmillanen_US
dc.subjectFeminist Studiesen_US
dc.titleGendering Drugsen_US
dc.typeBooken_US
Appears in Collections:Social Work

Files in This Item:
File Description SizeFormat 
37.pdf2.22 MBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.